2022
CTNI-57. RADIONUCLIDE THERAPY WITH 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA - INTERIM ANALYSIS RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY
Kurz S, Zan E, Cordova C, Barbaro M, Troxel A, Silverman J, Snuderl M, Zagzag D, Golfinos J, Kondziolka D, Sulman E. CTNI-57. RADIONUCLIDE THERAPY WITH 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA - INTERIM ANALYSIS RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY. Neuro-Oncology 2022, 24: vii85-vii85. DOI: 10.1093/neuonc/noac209.322.Peer-Reviewed Original ResearchSomatostatin receptor 2Progression-free survivalPhase II studyPFS-6Interim analysis resultsII studyIntracranial meningiomasClinical trialsMulticenter phase II studySomatostatin receptor 2 expressionInterim analysisPET-MRITreatment-limiting toxicityAggressive clinical courseCourse of radiationPET-MR imagingMethylation subclassesRadiotherapeutic optionsStable diseaseProgressive meningiomasOverall survivalNeuroendocrine tumorsSSTR2 expressionTumor measurementsTumor resection
2020
CTNI-53. SINGLE ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY OF THE RADIONUCLIDE 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA
Kurz S, Zan E, Gurewitz J, Cordova C, Troxel A, Sawaged Z, Sevillano-Torres H, Silverman J, Snuderl M, Zagzag D, Golfinos J, Kondziolka D, Sulman E. CTNI-53. SINGLE ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY OF THE RADIONUCLIDE 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA. Neuro-Oncology 2020, 22: ii54-ii55. PMCID: PMC7651467, DOI: 10.1093/neuonc/noaa215.219.Peer-Reviewed Original ResearchSomatostatin receptor 2Somatostatin receptor 2 expressionProgression-free survivalPhase II studyStandardized uptake valueIntracranial meningiomasPFS-6II studyBackground MeningiomasProgressive diseaseTreatment responseMulticenter phase II studyPET-MRIFunctional treatment responseCourse of radiationPrimary intracranial neoplasmsPET-MR imagingMethylation subclassesRadiotherapeutic optionsStable diseaseCTCAE gradeProgressive meningiomasOverall survivalNeuroendocrine tumorsSSTR2 expression